Eli Lilly’s Taltz Demonstrates Superiority Over Tremfya in Plaque Psoriasis Trial
Quick Summary Trial Result: Eli Lilly’s Taltz (ixekizumab) outperformed Janssen’s Tremfya (guselkumab) in a head-to-head Phase IV study. Primary Outcome: 41% of patients treated with